These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30588323)

  • 1. Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study.
    van Vollenhoven RF; Stohl W; Furie RA; Fox NL; Groark JG; Bass D; Kurtinecz M; Pobiner BF; Eastman WJ; Gonzalez-Rivera T; Gordon D
    Lupus Sci Med; 2018; 5(1):e000288. PubMed ID: 30588323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials.
    Furie R; Petri MA; Strand V; Gladman DD; Zhong ZJ; Freimuth WW;
    Lupus Sci Med; 2014; 1(1):e000031. PubMed ID: 25396065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychometric properties of FACIT-Fatigue in systemic lupus erythematosus: a pooled analysis of three phase 3 randomised, double-blind, parallel-group controlled studies (BLISS-SC, BLISS-52, BLISS-76).
    Rendas-Baum R; Baranwal N; Joshi AV; Park J; Kosinski M
    J Patient Rep Outcomes; 2021 Apr; 5(1):33. PubMed ID: 33830377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
    Furie R; Petri M; Zamani O; Cervera R; Wallace DJ; Tegzová D; Sanchez-Guerrero J; Schwarting A; Merrill JT; Chatham WW; Stohl W; Ginzler EM; Hough DR; Zhong ZJ; Freimuth W; van Vollenhoven RF;
    Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
    Brunner HI; Abud-Mendoza C; Mori M; Pilkington CA; Syed R; Takei S; Viola DO; Furie RA; Navarra S; Zhang F; Bass DL; Eriksson G; Hammer AE; Ji BN; Okily M; Roth DA; Quasny H; Ruperto N
    RMD Open; 2021 Sep; 7(3):. PubMed ID: 34531304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials.
    Abrahamowicz M; Esdaile JM; Ramsey-Goldman R; Simon LS; Strand V; Lipsky PE
    Arthritis Rheumatol; 2018 Sep; 70(9):1450-1458. PubMed ID: 29648686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel evidence-based systemic lupus erythematosus responder index.
    Furie RA; Petri MA; Wallace DJ; Ginzler EM; Merrill JT; Stohl W; Chatham WW; Strand V; Weinstein A; Chevrier MR; Zhong ZJ; Freimuth WW
    Arthritis Rheum; 2009 Sep; 61(9):1143-51. PubMed ID: 19714615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.
    Furie RA; Wallace DJ; Aranow C; Fettiplace J; Wilson B; Mistry P; Roth DA; Gordon D
    Arthritis Rheumatol; 2018 Jun; 70(6):868-877. PubMed ID: 29409143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SF-36v2 and FACIT-Fatigue quality of life improvements with organ-specific SELENA-SLEDAI response and belimumab treatment in patients with systemic lupus erythematosus.
    Rendas-Baum R; Chen WH; Gairy K; Anderson S; Henning C; Hammer A; Kosinski M
    Lupus Sci Med; 2024 May; 11(1):. PubMed ID: 38724182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of intravenous belimumab in a subgroup of South Korean patients with systemic lupus erythematosus enrolled into a Phase 3, randomized, placebo-controlled trial in North East Asia.
    Suh CH; Lee Y; Yoo SB; Quasny H; Navarro Rojas AA; Hammer A; Song YW; Kang YM; Cho CS; Park W; Kwok SK; Lee SG; Chung WT; Bae SC
    Int J Rheum Dis; 2024 Jan; 27(1):e14997. PubMed ID: 38140854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
    Navarra SV; Guzmán RM; Gallacher AE; Hall S; Levy RA; Jimenez RE; Li EK; Thomas M; Kim HY; León MG; Tanasescu C; Nasonov E; Lan JL; Pineda L; Zhong ZJ; Freimuth W; Petri MA;
    Lancet; 2011 Feb; 377(9767):721-31. PubMed ID: 21296403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of systemic lupus erythematosus responder index for detecting clinician-rated responders in patients with active systemic lupus erythematosus.
    Leosuthamas P; Narongroeknawin P; Chaiamnuay S; Asavatanabodee P; Pakchotanon R
    Int J Rheum Dis; 2023 Apr; 26(4):667-672. PubMed ID: 36802112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme.
    Maslen T; Bruce IN; D'Cruz D; Ianosev M; Bass DL; Wilkinson C; Roth DA
    Lupus Sci Med; 2021 Feb; 8(1):. PubMed ID: 33568389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus.
    Schwarting A; Dooley MA; Roth DA; Edwards L; Thompson A; Wilson B
    Lupus; 2016 Dec; 25(14):1587-1596. PubMed ID: 27488472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus.
    Doria A; Stohl W; Schwarting A; Okada M; Scheinberg M; van Vollenhoven R; Hammer AE; Groark J; Bass D; Fox NL; Roth D; Gordon D
    Arthritis Rheumatol; 2018 Aug; 70(8):1256-1264. PubMed ID: 29671280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials.
    Strand V; Levy RA; Cervera R; Petri MA; Birch H; Freimuth WW; Zhong ZJ; Clarke AE;
    Ann Rheum Dis; 2014 May; 73(5):838-44. PubMed ID: 23524886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repository corticotropin injection in patients with persistently active SLE requiring corticosteroids: post hoc analysis of results from a two-part, 52-week pilot study.
    Furie RA; Mitrane M; Zhao E; Becker PM
    Lupus Sci Med; 2017; 4(1):e000240. PubMed ID: 29344387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.
    Ginzler E; Guedes Barbosa LS; D'Cruz D; Furie R; Maksimowicz-McKinnon K; Oates J; Santiago MB; Saxena A; Sheikh S; Bass DL; Burriss SW; Gilbride JA; Groark JG; Miller M; Pierce A; Roth DA; Ji B
    Arthritis Rheumatol; 2022 Jan; 74(1):112-123. PubMed ID: 34164944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the Phase 2 clinical trial with blisibimod.
    Petri MA; Martin RS; Scheinberg MA; Furie RA
    Lupus; 2017 Jan; 26(1):27-37. PubMed ID: 27353505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.